alexa Survival Benefit Of Induction Immunosuppression In Cystic Fibrosis Lung Transplant Recipients | 33738
ISSN: 2161-0665

Pediatrics & Therapeutics
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Survival benefit of induction immunosuppression in Cystic fibrosis lung transplant recipients

3rd International Conference on Pediatrics

Stephen Kirkby

Nationwide Children’s Hospital, USA

Keynote: Pediat Therapeut

DOI: 10.4172/2161-0665.S1.014

Abstract
Background: Despite resistant microbes, induction immunosuppression is used in patients with Cystic Fibrosis (CF) undergoing Lung Transplantation (LTx). Methods: To evaluate the effect of induction immunosuppression on survival, the United Network for Organ Sharing (UNOS) was queried restricting analysis to transplant patients 6-55 years old from 2001-2012, who received induction agents (INDUCED) or did not (NONE). Results: A total of 1,721 CF patients who underwent LTx were included in the analysis; of these 791 (46%) were INDUCED. Of the INDUCED patients, 65% received basiliximab, 10% alemtuzumab, and 25% thymoglobulin/anti-lymphocyte globulin/antithymocyte globulin. Mean age was 28 years (SD=9.7) and 28.5 (SD=9.5) for the INDUCED and NONE groups, respectively. The median survival in the INDUCED group was 93.8 months (95% CI: 73.8) compared to 61.8 months (95% CI: 55.8-73.8) for the NONE group (log rank p-value <0.001). Conclusions: Antibody-based induction immunosuppression had a strong overall survival benefit in CF patients undergoing LTx.
Biography

Stephen Kirkby, MD is the Clinical Director of the Lung and Heart-Lung Transplant Programs at Nationwide Children’s Hospital and an Assistant Clinical Professor of Internal Medicine and Pediatrics at The Ohio State University College of Medicine. He graduated from Penn State University College of Medicine. He completed his residency training in internal medicine and pediatrics at Ohio State University Medical Center and Nationwide Children’s Hospital. He continued to complete training fellowships in adult pulmonary/critical care medicine and pediatric pulmonary medicine. He is board certified in internal medicine, pediatrics, adult pulmonary medicine, critical care medicine and pediatric pulmonary medicine.

Email: [email protected]

Leave Your Message 24x7
Top